Editas Medicine (NASDAQ:EDIT): Q2 GAAP EPS of -$0.69 misses by $0.06.
Revenue of $2.33M (-68.4% Y/Y) misses by $4.55M.
Shares -1.3%.
Tuesday, August 6, 2019
Aurinia Pharma EPS misses by $0.01, revenue in-line
Aurinia Pharma (NASDAQ:AUPH): Q2 GAAP EPS of -$0.17 misses by $0.01.
Revenue of $0.03M in-line (flat Y/Y).
Shares -0.33%.
GW Pharmaceuticals EPS beats by $0.23, beats on revenue
GW Pharmaceuticals (NASDAQ:GWPH): Q2 GAAP EPS of $0.21 beats by $0.23.
Revenue of $72.04M (+2083.0% Y/Y) beats by $26.47M.
Shares +7%.
MorphoSys AG reports Q2 results
MorphoSys AG (OTCPK:MPSYF): Q2 GAAP EPS of -€0.19.
Revenue of €34.7M (+328.4% Y/Y)
Pacific Biosciences of California EPS beats by $0.01, beats on revenue
Pacific Biosciences of California (NASDAQ:PACB): Q2 GAAP EPS of -$0.16 beats by $0.01.
Revenue of $24.62M (+14.1% Y/Y) beats by $3.83M.
Xeris Pharmaceuticals EPS misses by $0.32, beats on revenue
Xeris Pharmaceuticals (NASDAQ:XERS): Q2 GAAP EPS of -$1.28 misses by $0.32.
Grant income of $0.31M (-62.2% Y/Y) beats by $0.26M.
Cash and investments of $124.5M.
Akcea Therapeutics EPS beats by $0.05, beats on revenue
Akcea Therapeutics (NASDAQ:AKCA): Q2 GAAP EPS of -$0.40 beats by $0.05.
Revenue of $26.62M (+45.3% Y/Y) beats by $0.84M.
Subscribe to:
Posts (Atom)